Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Will someone report David Koos to the SEC? This is outrageous. I need to recoup some of my money and CANNOT Every negative thing that's been reported about him seems to be true.
cvinvestor's post 26299 - Please send a copy of your letter to Mr. Landers to the SEC. Let them keep it on file.
The article below is dated 4/11/16 from SEEKING ALPHA 4/11/16:
Regen Bio execs gets 10M-share payouts of preferred stock for resolving HemaXellerate clinical hold
Apr 11 2016, 07:29 ET | About: Regen Biopharma, Inc. (RGBP) | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip
In a regulatory filing, Regen Biopharma (OTCPK:RGBP) discloses that CEO David Koos, President & Chief Scientific Officer Harry Lander and CFO Tod Caven all received 10M shares of Series A Preferred Stock in consideration of their efforts in resolving the clinical hold issues related to lead product candidate HemaXellerate, a personalized cellular therapeutic that is designed to stimulate blood production in patients whose bone marrow is not working properly. A Phase 1 study in patients with drug-refractory aplastic anemia can now proceed. The company submitted its Investigational New Drug (IND) application to the FDA in February 2013.The company also issued 1M shares of Series A Preferred to settle a $10K debt.
Brakeman, with your Wharton School business degree, why demean that "degree" by investing in penny stocks? Nobody's impressed
Santosh Kesari, M.D., Ph.D., FANA who was hired by Regen is also on the scientific board of BATU
The info below appeared in Seeking Alpha about an hour ago:
Regen Biopharma, Inc. (RGBP) - OTCPK - Current
$0.170.0003(0.18%)
12:09 PM, 12/29 - Data Delayed 15 minutes
Regen Biopharma, Inc. stock chart
Today5d1m3m1y5y10y
52wk high:0.45
52wk low:0.08
EPS:N/A
PE (ttm):N/A
Div Rate:N/A
Yield:N/A
Market Cap:$19.37m
Volume:108,769
LATESTANALYSISBREAKING NEWSSTOCKTALK
All
Regen Bio on go to start early-stage study of HemaXellerate in aplastic anemia
In a regulatory filing, Regen Biopharma (OTCPK:RGBP) reports that it was informed by the FDA that it has satisfied all clinical hold issues related to its IND for HemaXellerate and it is cleared to initiate a Phase 1 trial in patients with drug-refractory aplastic anemia.HemaXellerate is a personalized cellular therapeutic that is designed to stimulate blood production in patients whose bone marrow is not working properly.
| Tue, Dec. 15, 8:24 AM | 5 Comments
Regen Bio's dCellVax IND on go
The FDA issues IND No. 16200 to Regen BioPharma (OTCPK:RGBP -1.9%) for a proposed Phase 1/2 clinical trial to evaluate dCellVax for the treatment for breast cancer. The one-year study will recruit 10 patients with metastatic breast cancer. Each will receive four monthly injections of the dCellVax gene silenced dendritic cell therapy. Patients will be assessed at six and twelve months.
| Nov. 4, 2014, 12:47 PM | 14 Comments
Regen Bio submits IND for breast cancer therapy candidate
Regen BioPharma (OTCPK:RGBP +13%) submits an IND to the FDA for clearance to begin a clinical trial to assess the safety and effectiveness of its immunotherapeutic product candidate, dCellVax, for the treatment of metastatic breast cancer.dCellVax's mode of action is silencing genes that suppress the body's immune response to cancer.
The following article appeared on 12/17/15 in Investor Wired:
Molycorp Inc (OTCMKTS:MCPIQ) was trading lower by -16.39% to $0.0250.So far, around 322,455 shares have changed hands in this session. After opening at $0.03, the stock hit as high as $0.03. However, it traded between $0.02 and $1.15 over the last twelve months. Molycorp Inc (OTCMKTS:MCPIQ) a development stage company, through its subsidiary, Regen BioPharma, Inc., intends to engage primarily in the development of regenerative medical applications. It develops HemaXellerate I, which is a patient-specific composition of cells that have been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies. The company is based in La Mesa, California.
Has BMSN Found The Bottom and Ready To Move Up? Find Out Here
Bio Matrix Scientific Group Inc (OTCMKTS:BMSN) was at $0.00020, showing a -33.33% decrease. Around 56.55 million shares have been traded, versus an-average trading volume of 26.33 million shares. Bio Matrix Scientific Group Inc (OTCMKTS:BMSN) produces and sells rare earths and rare metal materials in the United States and internationally. The company’s Resources segment extracts rare earth minerals, including light rare earth concentrates; rare earth oxides (REO), such as lanthanum, cerium, and neodymium-praseodymium; heavy rare earth concentrates, which include europium, gadolinium, terbium, dysprosium, and others; and SorbX and PhosFIX, a line of rare earth-based water treatment products. This segments products are used in oil refinery catalyst, automotive and emission catalysts, water purification, and energy efficiency lighting applications.
Kfox, I'm new at this. How do you lock in shares Thanks.
the following Seeking Alpha article was published on 12/1/15 under "Small Cap Solutions, LLC".
www.regenbiopharmainc.com (OTCPK:RGBP)
Regen BioPharma Inc. Attracts Top Researchers to Scientific Advisory Board
SAN DIEGO, December 1, 2015 /PRNewswire/ --
Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer andrecruits five distinguished scientists to join advisory team
Regen BioPharma, Inc., (RGBP) and (RGBP) today announced that Harry Lander, PhD, currently President of Regen Biopharma, Inc., would also serve as Chief Scientific Officer of the company. Regen also announced that five top researchers have agreed to serve on the company's scientific advisory board. Those researchers are Francesco Marincola, M.D., Ralph Nachman, M.D., Stefano Bertuzzi, Ph.D., Helen Sabzevari, Ph.D. and Lorraine Gudas, Ph.D.
Read More:
finance.yahoo.com/news/regen-biopharma-inc-attracts-top-133000314.html
Regen is optimistic that all concerns presented by the FDA have been addressed and that the FDA will grant clearance to the Company to initiate clinical trials on HemXellerate.
Regen is also developing and performing Pre Clinical Trial for numerous other new drugs for the treatment of : Breast, Liver, Prostate and Kidney Cancer, Leukemia, and Rare Blood Diseases/Disorders.
Regen is a likely candidate to be targeted for Buyout/Merger with a Large Pharma Co. or poised to become the Front Runner in Stem Cell Treatments.
Regen is a LONG PLAY with previously proven Short Term Gain potential of 35 to over 100 %.
SidVicious, since you know Regen is a "dog" just SELL your shares, move on and your stress-level whining will cease. GO REGEN
See Seeking Alpha's articles on RGBP and its potential. Also follow Robert E. Kreh's blog on small cap stocks GO RGBP, BMSN AND ENTB].
ChipnBella - My account is also with Sharebuilder and they are still waiting on RGBP for the divvies. Also, I was told that they don't hold Preferred Shares because of the following: There can be additional tax reporting requirements and trading requirements.
If what angelicsatan666 posted on 2/15/15 happens to be correct speculation and/or conjecture, then why hasn't anyone alerted the SEC and FINRA as to Koos' scheme and his welfare ATM? They are ready, willing and able investigate IMMEDIATELY BMSN, ENTB and RGBP before investors lose their money. FINRA's email is: marketregcomplaints@finra.org
I have spoken to FINRA about BMSN and the negativity surrounding the stock. Their advice is to send them an email so they can start looking at what's going on with BMSN, ENTB and RGBP. Their email address is: marketregcomplaints@finra.org
Contact BMSN's CPA. I have spoken to them in the past. They are:
Seale and Beers, CPAs, LLC - (702) 522-1645
FINRA's email applies only to THOSE INDIVIDUALS who are negatively speculating about BMSN
send an email to FINRA at: marketingcomplaints@finra.org. They could shed some light as to what's going on with BMSN
Phone FINRA and let them shed light on BMSN. Their number is: 301-590-6500. Based on the unprofessional performance of David R. Koos, the blogs are rightfully very negative and nobody wants to lose money
phone BMSN CPA/Underwriters: Seale and Beers, CPAs, LLC -
(702) 666-8588 or (702) 522-1645 Let them tell us what's going on. Koos is his own registered agent
WHERE IS DR. V?
Everyone, PLEASE, PLEASE Ignore Stockchaser. Truly, he's CLUELESS and he's an IDIOT to boot. He claimed sometime ago, he didn't receive his divvy and on and on he continued with the CRAP. Just ignore him. Your responses to him are not worth the time of day.
Pistol Pete, AWESOME and DILIGENT DD. You are fantastic.
Sharktank, stockchaser is CLUELESS and IRRELEVANT. That's why most intelligent bloggers on this board IGNORE HIM. He's an authority on EVERYTHING and KNOWS NOTHING
The PoPo - I'm glad you are back. You are a wealth of information. Very knowledgeable in your research for BMSN.
GO BMSN.
No, I haven't gotten mine as yet. I am with Sharebuilder